BRPI0607094A2 - composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica - Google Patents
composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêuticaInfo
- Publication number
- BRPI0607094A2 BRPI0607094A2 BRPI0607094-9A BRPI0607094A BRPI0607094A2 BR PI0607094 A2 BRPI0607094 A2 BR PI0607094A2 BR PI0607094 A BRPI0607094 A BR PI0607094A BR PI0607094 A2 BRPI0607094 A2 BR PI0607094A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- activity
- formula
- disease
- modulate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO DA FóRMULA I; USO DO COMPOSTO PARA O TRATAMENTO DE UMA DOENçA OU DISTúRBIO ASSOCIADO à ATIVIDADE EXCESSIVA DE BACE EM UM PACIENTE QUE DELE NECESSITA; USO DO COMPOSTO PARA MODULAR A ATIVIDADE DE BACE; E COMPOSIçãO FARMACêUTICA. A presente invenção fornece um composto de amino-piridina da fórmula I A presente invenção fornece também métodos para o seu uso para inibir <225>-secretase (BACE) e tratar depósitos <225>-amilóides e emaranhados neurofibrilares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64906805P | 2005-02-01 | 2005-02-01 | |
PCT/US2006/003186 WO2006083760A1 (en) | 2005-02-01 | 2006-01-26 | AMINO-PYRIDINES AS INHIBITORS OF β-SECRETASE |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607094A2 true BRPI0607094A2 (pt) | 2009-08-04 |
Family
ID=36481239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607094-9A BRPI0607094A2 (pt) | 2005-02-01 | 2006-01-26 | composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica |
Country Status (19)
Country | Link |
---|---|
US (2) | US7732457B2 (pt) |
EP (1) | EP1844035A1 (pt) |
JP (1) | JP2008528622A (pt) |
KR (1) | KR20070107062A (pt) |
CN (1) | CN101111489A (pt) |
AR (1) | AR053120A1 (pt) |
AU (1) | AU2006211159A1 (pt) |
BR (1) | BRPI0607094A2 (pt) |
CA (1) | CA2593857A1 (pt) |
CR (1) | CR9272A (pt) |
GT (1) | GT200600035A (pt) |
IL (1) | IL184303A0 (pt) |
MX (1) | MX2007009313A (pt) |
NO (1) | NO20073310L (pt) |
RU (1) | RU2007124935A (pt) |
SV (1) | SV2007002397A (pt) |
TW (1) | TW200639166A (pt) |
WO (1) | WO2006083760A1 (pt) |
ZA (1) | ZA200706345B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
AU2005264917A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
BRPI0512213A (pt) * | 2004-06-16 | 2008-02-19 | Wyeth Corp | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto |
US20080287399A1 (en) * | 2004-12-14 | 2008-11-20 | Astrazeneca Ab | Substituted Aminopyridines and Uses Thereof |
AU2006205127A1 (en) * | 2005-01-14 | 2006-07-20 | Wyeth | Amino-imidazolones for the inhibition of beta-secretase |
KR20070102751A (ko) * | 2005-02-14 | 2007-10-19 | 와이어쓰 | β-세크레타제 억제제로서의 아졸릴아실구아니딘 |
TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
AU2006266167A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
WO2007038271A1 (en) * | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
AU2006333049A1 (en) * | 2005-12-19 | 2007-07-12 | Wyeth | 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation |
WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
US7700606B2 (en) * | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
EP2064201A2 (en) * | 2006-09-21 | 2009-06-03 | Wyeth | Indolylalkylpyridin-2-amines for the inhibition of beta-secretase |
CN102838532A (zh) * | 2006-11-24 | 2012-12-26 | Ac免疫有限公司 | 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物 |
PE20090160A1 (es) * | 2007-03-20 | 2009-02-11 | Wyeth Corp | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA |
CL2008000791A1 (es) * | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
SG171708A1 (en) * | 2009-06-11 | 2011-07-28 | Abbott Lab | Anti-viral compounds to treat hcv infection |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
MX2012010657A (es) | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
CN102884060B (zh) * | 2010-03-24 | 2019-07-19 | 阿米泰克治疗方案公司 | 用于抑制激酶的杂环化合物 |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
US8921363B2 (en) | 2010-08-05 | 2014-12-30 | Amgen Inc. | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors |
CA2807419C (en) | 2010-08-18 | 2019-09-24 | Sunil Kumar Kc | Diketones and hydroxyketones as catenin signaling pathway activators |
EP2643325A1 (en) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
US8962859B2 (en) | 2011-02-15 | 2015-02-24 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
AU2014218720B2 (en) | 2013-02-22 | 2018-09-27 | Samumed, Llc | Gamma-diketones as Wnt/beta -catenin signaling pathway activators |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
WO2016029021A1 (en) | 2014-08-20 | 2016-02-25 | Samumed, Llc | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE45198B1 (en) | 1976-06-05 | 1982-07-14 | Wyeth John & Brother Ltd | Guanidine derivatives |
DE2901362A1 (de) | 1978-01-25 | 1979-07-26 | Sandoz Ag | Guanidinderivate, ihre herstellung und verwendung |
GB1588096A (en) | 1978-05-20 | 1981-04-15 | Wyeth & Bros Ltd John | Pyrrole derivatives |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
ZA967800B (en) | 1995-09-20 | 1997-04-03 | Yamanouchi Pharma Co Ltd | Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them |
GB9611046D0 (en) | 1996-05-25 | 1996-07-31 | Wivenhoe Techn Ltd | Pharmacological compounds |
GB2323841A (en) | 1997-04-04 | 1998-10-07 | Ferring Bv Group Holdings | Pyridine derivatives with anti-tumor and anti-inflammatory activity |
TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
DE10024319A1 (de) | 2000-05-17 | 2001-11-22 | Merck Patent Gmbh | Bisacylguanidine |
DE10046993A1 (de) | 2000-09-22 | 2002-04-11 | Aventis Pharma Gmbh | Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament |
AU2002352189A1 (en) * | 2001-11-30 | 2003-06-10 | Smithkline Beecham P.L.C. | Hydroxyethylene compounds with asp2 inhibitory activity |
WO2003053938A1 (en) | 2001-12-20 | 2003-07-03 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
US7053220B2 (en) | 2002-02-01 | 2006-05-30 | Elan Pharmaceuticals, Inc. | Hydroxyalkanoyl aminopyrazoles and related compounds |
WO2003094854A2 (en) | 2002-05-07 | 2003-11-20 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
GB0308318D0 (en) * | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
CA2523232A1 (en) * | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease |
US20070010532A1 (en) | 2003-07-01 | 2007-01-11 | Bayer Cropscience Gmbh | 3-Pyridylcarboxamide derivatives as pesticidal agents |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
MY149978A (en) | 2003-12-15 | 2013-11-15 | Merck Sharp & Dohme | Heterocyclic aspartyl protease inhibitors |
BRPI0512213A (pt) | 2004-06-16 | 2008-02-19 | Wyeth Corp | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto |
AU2005264917A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
AU2006205127A1 (en) | 2005-01-14 | 2006-07-20 | Wyeth | Amino-imidazolones for the inhibition of beta-secretase |
WO2006088705A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Terphenyl guanidines as [beta symbol] -secretase inhibitors |
KR20070102751A (ko) | 2005-02-14 | 2007-10-19 | 와이어쓰 | β-세크레타제 억제제로서의 아졸릴아실구아니딘 |
WO2006088694A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
AU2006266167A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
WO2007038271A1 (en) | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
AU2006333049A1 (en) | 2005-12-19 | 2007-07-12 | Wyeth | 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation |
WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
US7700606B2 (en) | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
-
2006
- 2006-01-26 CA CA002593857A patent/CA2593857A1/en not_active Abandoned
- 2006-01-26 WO PCT/US2006/003186 patent/WO2006083760A1/en active Application Filing
- 2006-01-26 RU RU2007124935/04A patent/RU2007124935A/ru not_active Application Discontinuation
- 2006-01-26 EP EP06719856A patent/EP1844035A1/en not_active Withdrawn
- 2006-01-26 BR BRPI0607094-9A patent/BRPI0607094A2/pt not_active IP Right Cessation
- 2006-01-26 CN CNA2006800036609A patent/CN101111489A/zh active Pending
- 2006-01-26 MX MX2007009313A patent/MX2007009313A/es unknown
- 2006-01-26 KR KR1020077019308A patent/KR20070107062A/ko not_active Application Discontinuation
- 2006-01-26 AU AU2006211159A patent/AU2006211159A1/en not_active Abandoned
- 2006-01-26 JP JP2007553315A patent/JP2008528622A/ja not_active Withdrawn
- 2006-01-27 TW TW095103606A patent/TW200639166A/zh unknown
- 2006-01-31 AR ARP060100342A patent/AR053120A1/es unknown
- 2006-01-31 US US11/344,432 patent/US7732457B2/en not_active Expired - Fee Related
- 2006-01-31 GT GT200600035A patent/GT200600035A/es unknown
- 2006-02-01 SV SV2006002397A patent/SV2007002397A/es not_active Application Discontinuation
-
2007
- 2007-06-28 IL IL184303A patent/IL184303A0/en unknown
- 2007-06-28 NO NO20073310A patent/NO20073310L/no not_active Application Discontinuation
- 2007-07-23 CR CR9272A patent/CR9272A/es not_active Application Discontinuation
- 2007-07-31 ZA ZA200706345A patent/ZA200706345B/xx unknown
-
2010
- 2010-04-20 US US12/763,612 patent/US20100204245A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101111489A (zh) | 2008-01-23 |
EP1844035A1 (en) | 2007-10-17 |
US7732457B2 (en) | 2010-06-08 |
CR9272A (es) | 2007-10-03 |
NO20073310L (no) | 2007-09-26 |
AR053120A1 (es) | 2007-04-25 |
WO2006083760A1 (en) | 2006-08-10 |
JP2008528622A (ja) | 2008-07-31 |
IL184303A0 (en) | 2007-10-31 |
SV2007002397A (es) | 2007-02-16 |
CA2593857A1 (en) | 2006-08-10 |
TW200639166A (en) | 2006-11-16 |
US20100204245A1 (en) | 2010-08-12 |
MX2007009313A (es) | 2007-09-12 |
RU2007124935A (ru) | 2009-03-10 |
ZA200706345B (en) | 2009-08-26 |
US20060173049A1 (en) | 2006-08-03 |
AU2006211159A1 (en) | 2006-08-10 |
KR20070107062A (ko) | 2007-11-06 |
GT200600035A (es) | 2006-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607094A2 (pt) | composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica | |
BRPI0606902A2 (pt) | composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica | |
BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BR0013122A (pt) | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
AR109170A2 (es) | Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente | |
BRPI0415397A (pt) | métodos e reagentes para o tratamento de desordens imunoinflamatórias | |
CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
BRPI0410041A (pt) | métodos para tratamento de dor de cabeça de sinusite | |
BRPI0512864A (pt) | composições e métodos para o tratamento de condições e desordens oculares | |
BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
BRPI0519181A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente | |
DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
ECSP088804A (es) | Antagonistas de los piridil amida de los canales de calcio de tipo t | |
BRPI0502346A (pt) | processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica | |
BRPI0607536A2 (pt) | tratamento de dor | |
MX2009011127A (es) | Metodo de prevencion y tratamiento de angiopatia amiloide cerebral. | |
ECSP067043A (es) | Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis | |
ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
AR060089A1 (es) | Tratamiento del dolor | |
DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2161 EM 05/06/2012 |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2165 DE 03/07/2012. |